Evidence map›Paper›PMID 40562412›Full record

ReviewJournal of neuroendocrinology2025

Controversies in NEN: An ENETS position statement on nutritional support in neuroendocrine neoplasms.

Simona Grozinsky-Glasberg, Johannes Hofland, Stephanie Alband, Yasmin Chotai de Lima, Adina Croitoru, Wanda Geilvoet, Peter Igaz, Beata Kos-Kudła, Guenter J Krejs, Alessandro Laviano and 5 more

Abstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neuroendocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Simona Grozinsky-GlasbergNeuroendocrine Tumor Unit, ENETS Center of Excellence, Division of Medicine, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University, Jerusalem, Israel.ORCID 0000-0002-1014-9154
Johannes HoflandDepartment of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0003-0679-6209
Stephanie AlbandPheo Para Alliance, Alexandria, Virginia, USA.
Yasmin Chotai de LimaTherapy and Neuroendocrine Tumour Unit, ENETS Center of Excellence, Royal Free Hospital, London, UK.
Adina CroitoruDepartment of Oncology, Fundeni Clinical Institute, Bucharest, Romania.
Wanda GeilvoetDepartment of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Peter IgazDepartment of Endocrinology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Beata Kos-KudłaDepartment of Endocrinology and Neuroendocrine Tumours, Medical University of Silesia, Katowice, Poland.ORCID 0000-0003-3755-1722
Guenter J KrejsDepartment of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.
Alessandro LavianoDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Francesco PanzutoDepartment of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy.ORCID 0000-0003-2789-4289
Anguraj SadanandamDivision of Cancer Biology, the Institute of Cancer Research, London, UK.
Ana Paula SantosEndocrinology Department and Precancerous Lesions and Early Cancer Management Group (PRECAM), Research Center of IPO Porto (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre (P.CCC), Porto, Portugal.ORCID 0000-0002-8896-305X
Staffan WelinDepartment of Endocrine Oncology, Uppsala University, Uppsala, Sweden.
Rajaventhan SrirajaskanthanDepartment of Gastroenterology, Neuroendocrine Tumour Unit, Kings College Hospital, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine neoplasms (NEN) themselves and also their treatment may cause malnutrition, inducing changes in physiological behaviour and eventually leading to increased rates of morbidity and mortality. Malnutrition is a common, under-recognised and under-treated condition in patients with NEN, and there are limited data available on the role of optimising nutrition in this setting. There are no formal evidence-based European Neuroendocrine Tumor Society (ENETS) guidelines on nutrition evaluation and management in patients with NEN to date. This manuscript was initiated during the 2024 ENETS Advisory Board meeting by using an expert panel consensus methodology and specific structured questions, which were identified and addressed through a structured review of the literature. The manuscript aims to identify the presence of specific nutrient deficits and define unmet needs and controversies regarding nutrition and NEN in a succinct manner, to promote collaborative and multidisciplinary research in the field, and to offer practical guidance in terms of how to assess malnutrition and dietary interventions by means of formulating a structured questionnaire.

Indexed as

MalnutritionNeuroendocrine TumorsNutritional SupportHumansSocieties, Medicaldietguidelinesneuroendocrine neoplasmsnutritionvitamin

Identifiers

PMID40562412
PMCPMC12678017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.